Jim Birchenough
Stock Analyst at Wells Fargo
(2.66)
# 2,144
Out of 4,974 analysts
36
Total ratings
45%
Success rate
23.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.55 | +265.50% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $54.86 | +27.60% | 3 | Feb 22, 2024 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $4.23 | +845.63% | 4 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $15.05 | +218.94% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.04 | +16,973.17% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.01 | +12,771.29% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $4.36 | +221.10% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $25.14 | +476.77% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $115.05 | -45.24% | 5 | Oct 29, 2020 | |
| RNA Avidity Biosciences | Initiates: Overweight | n/a | $50.36 | - | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 | $17.95 | +211.98% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $573.38 | +28.01% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $4.07 | +4,322.60% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $8.97 | +267.89% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.55
Upside: +265.50%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $54.86
Upside: +27.60%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $4.23
Upside: +845.63%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $15.05
Upside: +218.94%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.04
Upside: +16,973.17%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.01
Upside: +12,771.29%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $4.36
Upside: +221.10%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $25.14
Upside: +476.77%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $115.05
Upside: -45.24%
Avidity Biosciences
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $50.36
Upside: -
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $17.95
Upside: +211.98%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $573.38
Upside: +28.01%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $4.07
Upside: +4,322.60%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $8.97
Upside: +267.89%